Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 3 3Phase 1/2 3Phase 2/3 1

Status

Completed 4Terminated 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 6

Sponsor

Cancer Type

Other hematologic neoplasm 6Myeloid 2Lymphoid 2

Conditions

Leukemia, Myeloid, Acute 4Mastocytosis, Systemic 2Leukemia, Mast-Cell 2Aggression 2Leukemia 1Congenital Abnormalities 1

Interventions

Cyclophosphamide 517Bevacizumab 488Carboplatin 424pembrolizumab 388Paclitaxel 385Gemcitabine 372Cisplatin 366Docetaxel 323Rituximab 316Radiotherapy 296Nivolumab 247Doxorubicin 243Dexamethasone 240Fluorouracil 225Capecitabine 214Oxaliplatin 211Erlotinib Hydrochloride 206fludarabine phosphate 201Etoposide 188Cetuximab 186Lenalidomide 177Pemetrexed 176Bortezomib 174Trastuzumab 173Filgrastim 171fludarabine 166Prednisone 166Leucovorin 166Cytarabine 166Irinotecan 161

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2 × Has results × midostaurin × Clear all
NCT03836209 2025-06-15

Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia

PrECOG, LLC.

Phase 2 Active not recruiting
181 enrolled 18 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03280030 2025-03-20

A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML

Novartis

Phase 2 Completed
67 enrolled 21 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01883362 2021-03-17

RADIUS

Novartis

Phase 2 Completed
60 enrolled 17 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT00782067 2018-11-15

Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia

Novartis

Phase 2 Completed
116 enrolled 16 charts
LymphoidMyeloidOther hematologic neoplasm

Aggression, Leukemia, Leukemia, Mast-Cell, Mastocytosis, Systemic

NCT01846624 2018-09-27

Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Stanford University

Phase 2 Terminated
13 enrolled 12 charts
Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Myeloid, Acute

NCT00233454 2018-09-20

Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia

Stanford University

Phase 2 Completed
26 enrolled 12 charts
LymphoidMyeloidOther hematologic neoplasm

Aggression, Leukemia, Mast-Cell, Mastocytosis, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡